Aptinyx Inc. (APTX) News

Aptinyx Inc. (APTX): $0.07

0.00 (1.43%)

POWR Rating

Component Grades








Add APTX to Watchlist
Sign Up

Industry: Medical - Pharmaceuticals




#113 of 172

in industry

Filter APTX News Items

APTX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest APTX News From Around the Web

Below are the latest news stories about APTINYX INC that investors may wish to consider to help them evaluate APTX as an investment opportunity.

Horizon (HZNP) Q1 Earnings and Revenues Miss Estimates

Horizon Therapeutics (HZNP) reports lower-than-expected first-quarter 2023 results as it misses the Zacks Consensus Estimates for both revenues and earnings.

Yahoo | May 3, 2023

Anixa (ANIX) Falls 25% Despite Positive Breast Cancer Study Data

Anixa Biosciences (ANIX) announces positive top-line data from its phase Ia study evaluating the safety of its breast cancer vaccine. However, the stock plunges 25% in the absence of efficacy reports.

Yahoo | April 18, 2023

Agenus (AGEN) Rises on Fast Track Tag for Cancer Combo Drug

The FDA grants Fast Track Designation to Agenus' (AGEN) phase II study evaluating the botensilimab/balstilimab combination in non-MSI-H colorectal cancer patients. The stock jumps 16% following the news.

Yahoo | April 18, 2023

Adaptimmune (ADAP) Up 7%, Gets T-Cell Programs Rights From GSK

Adaptimmune Therapeutics (ADAP) enters into a transition deal with GSK to regain rights to its proprietary T-cell therapy programs. Shares of the company surges 7% following the news.

Yahoo | April 12, 2023

Merck (MRK) Keytruda Studies in Difficult-to-Treat Cancers Fail

Merck (MRK) and Eisai announce the discontinuation of the phase III LEAP-003 study seeking approval of the Keytruda and Lenvima combo. Another phase III LEAP-017 study fails to meet goals.

Yahoo | April 10, 2023

Seagen's (SGEN) Padcev & Keytruda Combo Gets FDA Accelerated Nod

The FDA grants accelerated approval to Seagen (SGEN) and partner, Astellas' combination therapy of Padcev with Merck's Keytruda for the treatment of first and second-line metastatic urothelial cancer.

Yahoo | April 4, 2023

Aptinyx Reports on Fourth Quarter and Full Year 2022 Results and Highlights and Review of Strategic Alternatives

EVANSTON, Ill., March 30, 2023--Aptinyx Inc. (Nasdaq: APTX) today reported recent business updates and financial results for the fourth quarter and full year 2022.

Yahoo | March 30, 2023

Here's Why Aptinyx Inc. (APTX) Is a Great 'Buy the Bottom' Stock Now

After losing some value lately, a hammer chart pattern has been formed for Aptinyx Inc. (APTX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Yahoo | March 30, 2023

Bicycle (BCYC) up on Collaboration With Novartis for Conjugates

Bicycle (BCYC) and Novartis enter into a collaboration agreement to develop, manufacture and commercialize conjugate drugs for several oncology indications. Stock soars following the news.

Yahoo | March 29, 2023

Vertex (VRTX) Inks Licensing Deal With CRISPR for Diabetes Drug

Vertex Therapeutics (VRTX) enters into a licensing agreement with CRISPR for the latter's gene-editing technology to accelerate the development of its type I diabetes hypoimmune therapy programs.

Yahoo | March 28, 2023

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 1.129 seconds.